Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly said its daily obesity pill met the company's goals in the first of several closely watched late-stage trials. The ...

A daily pill could be as effective for weight loss as popular drugs like Wegovy and Ozempic, providing an alternative to the ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

Eli Lilly shares are now positive for the year, up 10% since the start of January.

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

The first GLP-1 pill could be in medicine cabinets sooner than expected. Eli Lilly (LLY) announced Thursday that its daily ...